AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05959148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monochromatic infrared energy
Description: The monochromatic infrared energy was delivered through an Anodyne Therapy Professional Infrared Therapy System. Light energy (parameter: a wavelength of 890 nm and radiant power at a rate of 6.24 W) was produced through 8 array diode therapy pads applied on both knees (on the medial, lateral, anterior, and posterior aspects of each knee), each including 60 super-luminescent gallium-aluminum arsenide diodes. The MIRE was applied for 40 minutes/session, three times a week, for three successive months.
Study NCT05959148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: The traditional physical therapy program consisted of stretching and strengthening exercises for the muscles surrounding the hip and knee, balance exercises, as well as other electrotherapeutic modalities (ultrasound and hot application).
Study NCT05372172 — intervention group
Intervention type: OTHER
Intervention: none, observational study
Description: none, observational study
Study NCT06322654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotically Assisted Locomotion
Description: * Motor control training~* Locomotion and motor control training with elements of balance and coordination~* Verticalization training: standing frame device and vibration platform~* Cognitive therapy
Study NCT06322654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotically Assisted Verticalization
Description: * Motor control training~* Verticalization training with Standard Frame Devices~* Locomotion and motor control training with elements of balance and coordination~* Cognitive therapy
Study NCT06442878 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Belly Dance Program
Description: All Belly Dance sessions comprised 5 phases: 1) opening ritual (5 min), in which participants will be welcomed and perceived how people were feeling. 2) warm-up (15 min), in which thinking and feeling are integrated during the movements, isolating each part of the body according to Laban's body organization. 3) main phase (30 min), will be proposed individual, pair and group activities, in order to achieve the objectives planned. This phase will end with a choreography composition or a challenge; 4) cool-down (5 min) with stretching and physiological parameters normalization; and 5) ending ritual (5 min), in which the participants will be invented to share their sessions' experience.
Study NCT05907057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500mg Oral Tablet
Description: Provided as tablets, taken orally as two 250mg tablets once daily.
Study NCT05907057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
Study NCT06145620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: The intervention involves the visualization of different videos explaining the performance of lumbar strengthening exercises, measures for back care, and neuroscience pain education.
Study NCT06145620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The intervention involves the visualization of different videos explaining the performance of lumbar strengthening exercises, measures for back care, and neuroscience pain education.
Study NCT04857320 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: Human Insulin from recombinant source delivered in a solution capable of enabling transdermal delivery formulated at 100 IU/mL of delivery vehicle.
Study NCT06522022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Responsive SBIRT for OB
Description: SBIRT is a well-established enhanced screening preventive intervention model that is feasible and acceptable for use with trauma-exposed patients and in minoritized communities and can be delivered in the OB clinic during a prenatal care visit. The elements include:~1. standardized screening for PTSD and depression using the Primary Care Post Traumatic Stress Disorder Screen (PC-PTSD-5) and the Edinburgh Postnatal Depression Screening (EPDS) that will mirror brief screening practice;~2. explicit focus on concerns regarding mistrust,~3. psychoeducation on PTSD, depression, and the effects of trauma including medical trauma and traumatic loss on health/functioning,~4. motivational interviewing strategy components to promote awareness of psychological symptoms and engagement in culturally relevant resources including support/resources related to relevant social determinants of health,~5. teaching coping skills with culturally responsive technology tools
Study NCT06522022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Screening for PTSD
Description: This well-established 5-minute in-clinic interview includes administration of the PC-PTSD-5, a 5-item PTSD screening tool by trained medical staff (nurse, physician's assistant). Providers receive approximately one hour of training in trauma-informed care and how to administer the screening protocol. This method is regularly used in primary care clinic settings with trauma-exposed veterans and is validated for use in civilian samples, including low-income Black adults utilizing urban safety net hospital medical clinics.
Study NCT05576636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: Expectations regarding the scenario were explained to the participants before the implementation. They were given information about the standard patient. Roles were distributed, and the implementation time of the scenario was announced. Written permission was obtained from students involved in the scenario. The intervention group was given scenario-based education appropriate for the approach to a standard patient with COVID-19. During the implementation of the scenario, the instructor did not interfere with students, and after the feedback, the show-do method was used to improve the incorrect skill steps. Two instructors evaluated students' performance on the standard patient simulation as achieved-failed and the application was recorded as a pre-test.
Study NCT05576636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
Study NCT04910997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Combination of supervised and home-based aerobic exercise training
Study NCT04910997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: Combination of supervised and home-based aerobic exercise training
Study NCT04555616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Environmental Design
Description: Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.
Study NCT04555616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Environmental Design
Description: Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.
Study NCT04555616 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants' caregivers will receive a set script of placebo modifications.
Study NCT05631613 — intervention group
Intervention type: PROCEDURE
Intervention: cTACE(conventional transarterial chemoembolization)
Description: transarterial chemoembolization with lipiodol-idarubicin emulsion
Study NCT06216509 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endoscopic ultrasound pressure measurement
Description: all eligible patients from both groups will undergo Endoscopic ultrasound pressure measurement under sedation.
Study NCT05322473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab (M1095)
Description: randomized treatment; parallel-group
Study NCT05322473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: randomized treatment; parallel-group
Study NCT05322473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: randomized treatment; parallel-group
Study NCT05062499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TENS
Description: electrical stimulation
Study NCT05062499 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: no stimulation
Study NCT05593068 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: Pancreatic MRI
Study NCT05684211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ametumumab
Description: A recombinant fully human anti-EGFR monoclonal antibody
Study NCT05684211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody
Description: Toripalimab 3 mg/kg，Intravenous titration，Q2W
Study NCT05684211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 500 mg/m2 ，Intravenous titration，Q2W
Study NCT05684211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
Study NCT05335421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP) App
Description: The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
Study NCT06326567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C4 Program
Description: C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services.
Study NCT05078840 — intervention group
Intervention type: OTHER
Intervention: Evaluation of first line treatment in patients with stage I and II LBCL
Description: Evaluation of first line treatment in patients with stage I and II LBCL, without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP
Study NCT04896515 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Supplemental parenteral nutrition
Description: Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
Study NCT05067699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)
Description: The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
Study NCT05753696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d
Study NCT05753696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
Study NCT04749004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of physical activity
Description: Provision of motivational stimuli (commitment contracts, nudges, financial incentives) to increase amount of steps taken
Study NCT06070961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cellular immunity vs SARS-CoV-2
Description: Evaluation of cellular immunity vs SARS-CoV-2 by ELISpot assay
Study NCT06070961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Humoral immunity vs SARS-CoV-2
Description: Evaluation of Humoral immunity vs SARS-CoV-2 by ELISA assay (IgG anti-RBD and anti-N)
Study NCT06070961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cellular immunity vs Varicella Zoster Virus
Description: Evaluation of cellular immunity vs VZV by Enzyme-Linked immunoSPOT (ELISPOT) assay
Study NCT06070961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Humoral immunity vs Varicella Zoster Virus
Description: Evaluation of humoral immunity vs VZV by ELISA (VZV gE-binding IgG)
Study NCT06070961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diphtheria toxin-binding IgG
Description: Evaluation of diphtheria toxin-binding IgG by ELISA assay
Study NCT06070961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tetanus toxoid-binding IgG
Description: Evaluation of tetanus toxoid-binding IgG by ELISA assay
Study NCT06070961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T-cell populations and markers characterization
Description: Characterization of T-cell populations and markers by flow cytometry
Study NCT05298553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Participants will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Skylab CART-I ring followed by Apple Watch.
Study NCT05298553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B
Description: they will be asked to perform a simultaneous 30-seconds 12-lead ECG and single-lead ECG for each wearable device: Apple Watch followed by the Skylab CART-I ring.
Study NCT05155267 — intervention group
Intervention type: OTHER
Intervention: Biomonitoring study to detect MNPLs in biological samples and study of their health effects
Description: Determination of MNPLs levels, genotoxic damage and immunological effects
Study NCT04373252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT Lower Delivery (FMP 30)
Description: Participants will receive two fecal microbiota transplants via antegrade enema, one week apart.
Study NCT04857632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: atorvastatin 20mg per day for 7 days
Study NCT05761548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrafast ultrasound power Doppler imaging
Description: ultrafast ultrasound power Doppler imaging for neonatal brain microvessels
Study NCT05401097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT05401097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of the bone marrow
Study NCT05401097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO
Study NCT05401097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO
Study NCT05401097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06441240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Breast MRI
Study NCT06356896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diaphragmatic breathing exercise
Description: Each patient's relative should not be in the room, the curtains/screens around the patient bed should be closed, and interventions should be applied in a comfortable environment care will be taken to ensure that the room is quiet and calm. During the first 5 minutes, researchers will explain with pictures how the exercise is done and show it to the patient. The patient will then be asked to perform the exercise for 10 minutes under the supervision of the researchers. If the patient has performed the DBE correctly, the procedure will be discontinued. Otherwise, the patient will be asked to practice for another 5 minutes. If at the end of this period the patient still cannot perform the exercise correctly, he will be removed from the sample. DBE will be performed according to Cleveland Clinic guidelines.
Study NCT04693624 — intervention group
Intervention type: OTHER
Intervention: Hormonal levels
Description: A total of ten (10) blood samples (2ml/each) will be collected during the study for subsequent analysis of progesterone, hCG, inhibin-A, and 17-OH-progesterone:~Day of triggering (before the injection of hCG, appx. 6 pm) Twelve (12 hours) after hCG injection (appx. at 6 am) Twenty-four (24) hours after hCG injection (appx. at 6 pm) Thirty-six (36) hours after hCG injection (appx. at 8 am, 2 hours after OPU) One (1) day after OPU (60h after hCG) (appx. at 6 am) Two (2) days after OPU (84h after hCG) (appx. at 6 am) Three (3) days after OPU 108h after hCG) (appx. at 6 am) Four (4) days after OPU (132h after hCG) (appx. at 6 am) Five (5) days after OPU (156h after hCG) (appx. at 6 am) Six (6) days after OPU (180h after hCG) (appx. at 6 am)
Study NCT05346419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: Participants received risedronate 35 mg once a week for 6 months.
Study NCT05346419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
Study NCT05556044 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 MG
Description: This is an investigator-initiated, prospective, single-centre, non-randomized open label study that evaluates the efficacy and safety of initiating empagliflozin during index hospitalization for acute heart failure regardless of LVEF.
Study NCT04029077 — intervention group
Intervention type: OTHER
Intervention: NA: intervention is not part of the study
Description: NA: it is not an interventional study
Study NCT05727852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test using the Compact PTR-TOF-MS
Description: Breath samples will be analyzed with a proton-transfer reaction mass spectrometer (Compact PTR-MS, Ionicon, Austria) to obtain eVOCs profiles listed as ions at various mass-to-charge ratios (m/z).
Study NCT05727852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Portable cardiac monitor CardioQvark
Description: Record an electrocardiogram (ECG) in one lead with an assessment of the pulse wave using a portable cardiac monitor CardioQvark (Russia, LLC L Card , RU No. RZN 2019/8124 dated February 15, 2019) once. Devices automatically transfer data to the A\&D Connect app paired with it (link). When transferring data, they are completely protected. The data obtained using the application must be sent to the specialists of the research group in a depersonalized form.
Study NCT05727852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of arterial stiffness using the VaSera VS-1500N
Description: Assessment of arterial stiffness using the VaSera VS-1500N Fukuda Denshi device by non-invasive measurement of blood pressure in four limbs with simultaneous recording of ECG, PCG and pulse waves on the carotid, femoral arteries, as well as on the arteries of four limbs.
Study NCT06320262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet cupping therapy (WCT)
Description: Type of cupping: Triple-stage wet cupping therapy (Hijama) will be used; sucking, scarification, sucking.~Cupping points will include one cup on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra (Alkahil area); two points in the inter-scapular region 3cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra, two points at inferior angle of the scapula (3cm lateral to lower border of the spinous process of the 7th thoracic vertebra, 2 points at lumbar regions, in addition to the most painful areas.~After the procedure: Areas of cupping will be covered using sterile gauze. All used tools and materials will be collected in red bags to ensure proper waste disposal. Sharp objects will be disposed of in the sharps disposal box. Telephone follow-up with all patients 48 hours after cupping will be done.
Study NCT05242120 — intervention group
Intervention type: OTHER
Intervention: Survey to access the impact of COVID 19 on anesthesia residency
Description: This is a cross-sectional study using an online survey will be conducted on 75 anesthesia residents in Cairo University hospitals. Invitations were sent to residents' groups on WhatsApp. Study objectives were clearly explained at the beginning of the survey, and the participants were encouraged to roll out the survey to as many physicians as possible. This survey contains 62-question, divided into four main sections